Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis

LAG-3 and TIGIT protein expressions in cutaneous melanoma and their relationship with PD-1 tumor-infiltrating lymphocytes

(2019) Woo Jin Lee et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).

(2019) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

(2019) T Yau et al.   ANNALS OF ONCOLOGY

Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma

(2018) Chao-Qun Liu et al.   BRITISH JOURNAL OF CANCER

PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma

(2018) Vinod Varki et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

LAG-3 in Non–Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival

(2018) Sigurd M. Hald et al.   Clinical Lung Cancer

Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases

(2018) Jorge A. Marrero et al.   HEPATOLOGY

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma

(2018) Biwei Yang et al.   Nature Communications

OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment, specific mutation signature, and poor prognosis

(2018) Kunlin Xie et al.   OncoImmunology

LAG3 (CD223) as a cancer immunotherapy target

(2017) Lawrence P. Andrews et al.   IMMUNOLOGICAL REVIEWS

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes

(2017) Yayi He et al.   Journal of Thoracic Oncology

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

(2017) Edwin R. Parra et al.   Scientific Reports

PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma

(2017) Kostandinos Sideras et al.   OncoImmunology

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

(2016) Elizabeth D Thompson et al.   GUT

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Pathological  -synuclein transmission initiated by binding lymphocyte-activation gene 3

(2016) X. Mao et al.   SCIENCE

LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma

(2016) Wei-Wei Deng et al.   OncoImmunology

Clec4g (LSECtin) interacts with BACE1 and suppresses Aβ generation

(2015) Yasuhiko Kizuka et al.   FEBS LETTERS

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

(2015) T. Kouo et al.   Cancer Immunology Research

LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

(2014) F. Xu et al.   CANCER RESEARCH

Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients

(2012) Fu-Jun Li et al.   IMMUNOLOGY LETTERS

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice

(2011) Taku Okazaki et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The DC-SIGN family member LSECtin is a novel ligand of CD44 on activated T cells

(2010) Li Tang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions

(2009) K. Wu et al.   CANCER RESEARCH

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

(2009) Q. Gao et al.   CLINICAL CANCER RESEARCH

Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells

(2009) J. F. Grosso et al.   JOURNAL OF IMMUNOLOGY

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE